Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
79.16
+0.06 (+0.08%)
Official Closing Price
Updated: 4:10 PM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
87
88
Next >
Price Over Earnings Overview: Merck & Co
June 09, 2025
Via
Benzinga
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
June 09, 2025
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.
Via
Benzinga
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish
June 09, 2025
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide.
Via
Stocktwits
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
June 09, 2025
Via
Benzinga
Top S&P500 movers in Monday's pre-market session
June 09, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Via
Chartmill
Unpacking the Latest Options Trading Trends in Merck & Co
June 04, 2025
Via
Benzinga
How Do Investors Really Feel About Merck & Co?
May 30, 2025
Via
Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
June 07, 2025
Each of the index's highest-yielding names has its own unique story right now.
Via
The Motley Fool
Topics
Economy
Stocks
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
June 06, 2025
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.
Via
Benzinga
Topics
Bankruptcy
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
June 05, 2025
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.
Via
Benzinga
9 Health Care Stocks Whale Activity In Today's Session
June 04, 2025
Via
Benzinga
1 Value Stock to Target This Week and 2 to Question
June 04, 2025
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...
Via
StockStory
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
June 03, 2025
The deal is being discussed ahead of key data from MoonLake in patients with a skin disease.
Via
Investor's Business Daily
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
June 03, 2025
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.
Via
Benzinga
Topics
Intellectual Property
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers
May 30, 2025
Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.
Via
Benzinga
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
May 30, 2025
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
Via
Investor's Business Daily
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
May 30, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’
May 29, 2025
The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated.
Via
Stocktwits
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
May 29, 2025
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
May 27, 2025
Via
Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals
May 27, 2025
MERCK & CO. (NYSE:MRK) offers a strong 4.2% dividend yield, consistent growth, and solid financial health, making it a top pick for dividend investors.
Via
Chartmill
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy."
May 27, 2025
Via
The Motley Fool
Topics
Earnings
Economy
World Trade
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
May 23, 2025
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
Via
Investor's Business Daily
3 Dow Jones Stocks on Our Watchlist
May 23, 2025
The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership...
Via
StockStory
Topics
Stocks
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
May 22, 2025
Via
Benzinga
Moderna Stock Looks Ripe for a Short Squeeze
May 22, 2025
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze
Via
MarketBeat
Topics
Government
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
May 21, 2025
Via
The Motley Fool
Topics
Economy
Law Enforcement
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
May 20, 2025
Via
Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals
May 20, 2025
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector.
Via
Chartmill
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
May 18, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
87
88
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.